Salvat
Focus: Salvat is a mid-size biotech company headquartered in Miami with 201–500 employees, specializing in small-molecule therapeutics for ophthalmology and immunology. The company derives 100% of revenue from OTOVEL, a ciprofloxacin/fluocinolone combination ear drop.
Profile data last refreshed 5h ago · AI intelligence enriched 3w ago
Employees
201-500
Open Jobs
10-5 this month
Cooling — net -5 jobs in 30d
0 added, 5 removed. Slower than typical.
Should You Work at Salvat?
AI assessmentSalvat presents a high-risk, high-reward opportunity for early-career scientists willing to bet on pipeline success and imminent launches, but financial concentration and lack of visible R&D hiring suggest organizational instability.
Why Work Here
- Active late-stage pipeline with 10 Phase 3 programs across ophthalmology and otic indications, offering exposure to clinical development and launch strategy.
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Late-stage
10 Phase 3+
LOE Risk
1 in 5yr
OTOVEL
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$4K Part DDeclining
Peak
Help build intelligence for Salvat
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.